AliveDx Submits 510(k) Notification to the FDA for Innovative Vasculitis Test AliveDx has announced the submission of its 510(k) notification to the FDA for the MosaiQ AiPlex® Vasculitis test, enhancing diagnostic capabilities for autoimmune conditions.

AliveDx Submits 510(k) Notification to the FDA for Innovative Vasculitis Test #USA #AliveDx #Eysins #MosaiQ_AiPlex #Vasculitis_Test

AliveDx Submits 510(k) Application for the MosaiQ AiPlex® Vasculitis Assay to FDA AliveDx has announced the submission of a 510(k) application to the FDA for its innovative MosaiQ AiPlex® Vasculitis assay aimed at improving diagnoses of autoimmune diseases.

AliveDx Submits 510(k) Application for the MosaiQ AiPlex® Vasculitis Assay to FDA #USA #FDA_Approval #AliveDx #Eysins #MosaiQ_AiPlex

AliveDx Takes Significant Steps with FDA Submission for MosaiQ AiPlex® Vasculitis Assay AliveDx has officially submitted its MosaiQ AiPlex® Vasculitis assay for FDA clearance, aspiring to enhance diagnostic solutions for autoimmune vasculitis, improving patient outcomes.

AliveDx Takes Significant Steps with FDA Submission for MosaiQ AiPlex® Vasculitis Assay #USA #AliveDx #Eysins #MosaiQ_AiPlex #FDA_Submission

MosaiQ AiPlex® Vasculitis Test Now Available for Clinical Use in Europe The MosaiQ AiPlex® Vasculitis test is now clinically available in the EU and other CE-mark accepted countries, revolutionizing autoimmune diagnostics.

MosaiQ AiPlex® Vasculitis Test Now Available for Clinical Use in Europe #Switzerland #AliveDx #Eysins #MosaiQ_AiPlex #Vasculitis

AliveDx Launches MosaiQ AiPlex® Vasculitis Assay for Clinical Use in Europe AliveDx has announced the clinical availability of its MosaiQ AiPlex® Vasculitis assay across Europe, streamlining autoimmune diagnostics and enhancing patient care.

AliveDx Launches MosaiQ AiPlex® Vasculitis Assay for Clinical Use in Europe #None #AliveDx #MosaiQ_AiPlex #Vasculitis

AliveDx Launches Innovative MosaiQ AiPlex® Vasculitis Assay in Europe AliveDx has introduced the MosaiQ AiPlex® Vasculitis assay for clinical use in Europe, streamlining diagnosis and improving outcomes for autoimmune conditions.

AliveDx Launches Innovative MosaiQ AiPlex® Vasculitis Assay in Europe #None #AliveDx #MosaiQ_AiPlex #Vasculitis

AliveDx Seeks FDA Approval for Revolutionary Multiplex Biochip Technology AliveDx has taken a significant step by submitting a 510(k) premarket notification to the FDA for its innovative multiplex biochip MosaiQ AiPlex® CTDplus. This technology aims to improve autoimmune disease diagnostics.

AliveDx Seeks FDA Approval for Revolutionary Multiplex Biochip Technology #USA #AliveDx #Eysins #MosaiQ_AiPlex #FDA_510(k)

AliveDx Submits 510(k) Application for MosaiQ AiPlex CTDplus Microarray to FDA AliveDx has filed a 510(k) application for the innovative MosaiQ AiPlex CTDplus microarray, targeting advancements in connective tissue disease diagnostics.

AliveDx Submits 510(k) Application for MosaiQ AiPlex CTDplus Microarray to FDA #USA #AliveDx #Eysins #MosaiQ_AiPlex #CTDplus

AliveDx Submits 510(k) Application for Advanced CTD Multiplex Microarray to the US FDA AliveDx has announced the submission of a 510(k) premarket notification to the FDA for its groundbreaking MosaiQ AiPlex CTDplus multiplex microarray, aimed at improving autoimmune disease diagnoses.

AliveDx Submits 510(k) Application for Advanced CTD Multiplex Microarray to the US FDA #USA #AliveDx #Eysins #MosaiQ_AiPlex #FDA_510(k)

AliveDx Submits Notice to FDA for Advanced Celiac Disease Testing Solution AliveDx has announced the submission of its 510(k) premarket notification to the FDA for the MosaiQ AiPlex® Celiac Disease microarray, enhancing diagnosis speed.

AliveDx Submits Notice to FDA for Advanced Celiac Disease Testing Solution #USA #AliveDx #MosaiQ_AiPlex #Celiac_Disease #Eysins,_Switzerland

AliveDx's Innovative MosaiQ AiPlex Aims to Transform Celiac Disease Diagnosis in the U.S. AliveDx has submitted a 510(k) application to the FDA for its MosaiQ AiPlex microarray, promising faster, accurate diagnoses for celiac disease.

AliveDx's Innovative MosaiQ AiPlex Aims to Transform Celiac Disease Diagnosis in the U.S. #USA #AliveDx #Eysins #MosaiQ_AiPlex #Celiac_Disease

AliveDx Files 510(k) Submission with FDA for Innovative MosaiQ AiPlex® Celiac Disease Test AliveDx has officially submitted a 510(k) premarket notification to the FDA for its groundbreaking MosaiQ AiPlex® Celiac Disease microarray, promising rapid and accurate diagnoses.

AliveDx Files 510(k) Submission with FDA for Innovative MosaiQ AiPlex® Celiac Disease Test #USA #AliveDx #Eysins #MosaiQ_AiPlex #Celiac_Disease

AliveDx Submits 510(k) Application for MosaiQ AiPlex® Celiac Disease Test to FDA AliveDx has announced the submission of a 510(k) premarket notification to the FDA for their MosaiQ AiPlex® Celiac Disease test, aiming to enhance diagnostic efficiency.

AliveDx Submits 510(k) Application for MosaiQ AiPlex® Celiac Disease Test to FDA #USA #AliveDx #Eysins #MosaiQ_AiPlex #Celiac_Disease

AliveDx Submits FDA 510(k) for MosaiQ AiPlex® Celiac Disease Test to Revolutionize Diagnosis AliveDx has submitted a 510(k) notification to the FDA for MosaiQ AiPlex® Celiac Disease microarray, promising faster, more accurate diagnostics.

AliveDx Submits FDA 510(k) for MosaiQ AiPlex® Celiac Disease Test to Revolutionize Diagnosis #USA #AliveDx #Eysins #MosaiQ_AiPlex #Celiac_Disease